

MARINOMED BIOTECH AG

ISIN: ATMARINOMED6 WKN: - Asset Class: **Stock**

Company

2021/10/20 17:35:03

Price

105.00

EUR

Difference

-2.78%(-3.00)



Contact Details

MARINOMED BIOTECH AG Tel: 43-1-2262-90300
 -- Fax: 43-1-25077-4493
 Hovengasse 25 Web: <http://www.marinomed.com>
 2100 Korneuburg E-mail: office@marinomed.com

Company Profile

Marinomed Biotech AG is a biopharmaceutical company, which engages in the development of therapies based on patent protected technology platforms. It operates through the Carragelose and Marinosolv segments. The Carragelose segment contains products with anti-viral properties target viral infections of the respiratory tract of different virus strains. The Marinosolv segment refers to the technology platform that increases the bioavailability of hardly soluble compounds for the treatment of sensitive tissues such as nose and eyes. The company was founded by Andreas Grassauer and Eva Prieschl-Grassauer in 2006 and is headquartered in Korneuburg, Austria.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2020		2019		2018	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	15,396,000		15,337,000		3,723,000	
Common stock capital		1,472,000		1,469,000		1,000,000
Fixed assets	8,105,000		4,164,000		1,540,000	
Equity capital of a company		5,357,000		10,866,000		-16,267,000
Cash and cash equivalents	9,206,000		12,019,000		1,715,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		5,608,000		4,026,000		7,641,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		12,535,000		4,609,000		13,888,000
Different income		-		-		-
Other liabilities		78,000		104,000		7,131,000
Total assets	23,501,000	23,501,000	19,501,000	19,501,000	5,263,000	5,263,000

Balance notes

	2020	2019	2018
Accounting standard	IFRS	IFRS	IFRS
Employees	37	31	32
Equity ratio	22.80%	55.72%	-309.06%
Debt-equity ratio	338.66%	79.47%	-132.36%

Others

	2020	2019	2018
Tax Expense Rate	-0.06%	-0.06%	-0.03%

MARINOMED BIOTECH AG

ISIN: ATMARINOMED6 WKN: - Asset Class: **Stock**

Income statement

	2020	2019	2018
Turnover	8,124,000	6,144,000	4,666,000
Net income	-6,010,000	-7,216,000	-12,096,000
EBIT	-5,293,100	-6,547,000	-10,597,749
Operating income before taxes	-6,006,000	-7,212,000	-12,093,000
Cash Flow	-6,885,000	-7,640,000	-4,315,000
Net interest income	-713,000	-665,000	-1,495,000
Research and development expenses	5,942,000	4,775,000	2,934,000
Income taxes	3,000	4,000	3,000
Result from investments in subsidiaries, associates and other	0	-	0
Revenues per employee	219,578	198,213	145,821

Board of Directors

Simon Jules Nebel	Chairman of Supervisory Board
Gernot Hofer	Member of Supervisory Board
Brigitte Ederer	Member of Supervisory Board
Ute Lassnig	Member of Supervisory Board

Members of Management Board

Andreas Grassauer	Chairman of Managing Board
Eva Prieschl-Grassauer	Member of Executive Committee
Pascal Schmidt	Member of Executive Committee